Increased dose of echinocandins for invasive fungal infections: bonanza for the patient or the pharmaceutical industry?

Bone Marrow Transplant. 2007 Feb;39(3):129-31. doi: 10.1038/sj.bmt.1705563.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antifungal Agents / therapeutic use
  • Dose-Response Relationship, Drug
  • Drug Industry / economics
  • Echinocandins
  • Fungal Proteins / therapeutic use*
  • Humans
  • Mycoses / drug therapy*
  • Peptides, Cyclic / therapeutic use*

Substances

  • Antifungal Agents
  • Echinocandins
  • Fungal Proteins
  • Peptides, Cyclic
  • echinocandin B